Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zelicapavir (Primary)
Indications Respiratory syncytial virus infections; Respiratory tract infections
Focus Therapeutic Use
Acronyms RSVP
Sponsors Enanta Pharmaceuticals

18 May 2022 According to an Enanta Pharmaceuticals media release, data from this trial will be presented at a future medical meeting or in a peer-reviewed publication.
18 May 2022 Primary endpoint ( Effect of EDP-938 compared to placebo on RSV infection clinical symptoms measured as the total symptom score (TSS) area under the curve (AUC) from Day 1 through Day 14) has not been met as per Enanta Pharmaceuticals Media Release
18 May 2022 Results published in the Enanta Pharmaceuticals Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com